
FDA Approves Generic Binimetinib for BRAF-Mutant Melanoma and NSCLC
Alembic's generic binimetinib, in 15 mg and 45 mg tablets, is therapeutically equivalent to Mektovi for BRAF-mutant melanoma and NSCLC.
The FDA has granted final approval to Alembic Pharmaceuticals' abbreviated new drug application (ANDA) for binimetinib tablets, 15 mg and 45 mg, a generic version of binimetinib (Mektovi), according to a November 14, 2026, announcement from the company.1 The approved product is therapeutically equivalent to the reference listed drug, Mektovi 15 mg tablets, from Array BioPharma, a subsidiary of Pfizer.1,2 The release did not state when the generic will launch in the United States.1
Binimetinib is a kinase inhibitor that inhibits MEK and is used in combination with the BRAF inhibitor encorafenib (Braftovi).1,2 The reference product is supplied only as 15 mg tablets, so a 45 mg tablet is a new strength for patients and clinicians in the United States.2
Which patients is generic binimetinib approved for?
According to the release, the generic shares the indications of the reference product:
- In combination with encorafenib, for patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation
- In combination with encorafenib, for adults with metastatic non–small cell lung cancer (NSCLC) with a BRAF V600E mutation
The reference label calls for confirming the BRAF mutation before treatment begins.2 The recommended dose is 45 mg orally twice daily with encorafenib, taken with or without food; for patients with moderate or severe hepatic impairment, the recommended dose is 30 mg twice daily.2
What does the approval mean for access?
Alembic was one of the first ANDA applicants for the 15 mg strength and the sole first applicant for the 45 mg strength, having filed substantially complete ANDAs with Paragraph IV certifications, and is eligible for 180 days of generic drug exclusivity for both strengths.1 Alembic had received tentative FDA approval for the 15 mg strength and, in June 2026, for the 45 mg strength.3
Array BioPharma and Alembic settled patent-infringement litigation over the drug in June 2025; the terms of that settlement were not disclosed.4 Citing IQVIA data, Alembic reported that binimetinib tablets had US sales of about $282 million in the 12 months ending September 2026.1 The approval brings the company's cumulative FDA ANDA approvals to 248, including 230 final and 18 tentative approvals.1 The release did not include pricing information.1
What data support encorafenib plus binimetinib?
A generic approval relies on the efficacy and safety established for the reference product. Encorafenib plus binimetinib was first approved in melanoma based on the phase 3 COLUMBUS trial (NCT01909453), which randomly assigned 577 patients with BRAF V600E- or V600K-mutant unresectable or metastatic melanoma.5 Median progression-free survival was 14.9 months with encorafenib plus binimetinib vs 7.3 months with vemurafenib (HR, 0.54; 95% CI, 0.41-0.71; P < .0001).5 In a
In NSCLC, approval was based on the single-arm phase 2 PHAROS study (NCT03915951) of 98 patients with BRAF V600E-mutant metastatic disease.7 The objective response rate was 75% among 59 treatment-naive patients and 46% among 39 previously treated patients, as was
What safety considerations apply to binimetinib?
Warnings and precautions on the reference label include the following:
- Cardiomyopathy: assess left ventricular ejection fraction before treatment, after 1 month, and every 2 to 3 months thereafter
- Ocular toxicities: serous retinopathy, retinal vein occlusion, and uveitis have occurred; perform ophthalmologic evaluation at regular intervals and for any visual disturbances
- Venous thromboembolism, interstitial lung disease, hemorrhage, and new primary malignancies
- Hepatotoxicity: monitor liver function tests before and during treatment
- Rhabdomyolysis: monitor creatine phosphokinase and creatinine periodically
- Embryo-fetal toxicity: advise females of reproductive potential to use effective contraception
The most common adverse reactions (25% or more) with binimetinib plus encorafenib in melanoma were fatigue, nausea, diarrhea, vomiting, and abdominal pain. In NSCLC, they also included musculoskeletal pain, visual impairment, constipation, dyspnea, rash, and cough.2
What are the key takeaways for oncology nurses?
- Generic binimetinib is FDA approved, but no US launch date has been announced.1
- The 45 mg tablet differs from the reference product's 15 mg tablets; pharmacy, order sets, and patient teaching should confirm the strength dispensed, particularly when the dose is lowered, such as to 30 mg twice daily for hepatic impairment.2
- Binimetinib is always given with encorafenib, and patients need confirmation of a BRAF mutation before starting.1,2
- Baseline and serial LVEF assessment, regular eye examinations, liver function tests, and creatine phosphokinase monitoring are unchanged with a generic product.2
- Patients should report visual changes, shortness of breath, leg swelling, bleeding, or muscle pain promptly.2
- Generic availability may affect out-of-pocket costs for an oral agent, a topic for financial navigation once the product launches.1
References
- Alembic Pharmaceuticals Limited receives USFDA final approval for binimetinib tablets, 15 mg and 45 mg. News release. Alembic Pharmaceuticals. November 14, 2026. Accessed November 16, 2026.
https://alembicpharmaceuticals.com/webfiles/media/2026-2027/Press-Release-Binimetinib-Tablets-15-mg-and-45-mg.pdf - Mektovi. Prescribing information. Array BioPharma Inc; 2024. Accessed November 16, 2026.
https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/210498s010lbl.pdf - Nasim F. Alembic secures USFDA tentative approval for generic cancer drug binimetinib. Medical Dialogues. June 19, 2026. Accessed November 16, 2026.
https://medicaldialogues.in/amp/news/industry/pharma/alembic-secures-usfda-tentative-approval-for-generic-cancer-drug-binimetinib-eyes-180-day-exclusivity-173260 - Pfizer settles with final defendant in Mektovi patent lawsuit. Bloomberg Law. June 10, 2025. Accessed November 16, 2026.
https://news.bloomberglaw.com/ip-law/pfizer-settles-with-final-defendant-in-mektovi-patent-lawsuit - FDA approves encorafenib and binimetinib in combination for unresectable or metastatic melanoma with BRAF mutations. Oncology Nursing Society. June 2018. Accessed November 16, 2026.
https://www.ons.org/publications-research/voice/news-views/06-2018/fda-approves-encorafenib-and-binimetinib-combination - Fischer L. Encorafenib/binimetinib showcases sustained responses in BRAF V600–mutant melanoma. Oncology Nursing News. October 20, 2022. Accessed November 16, 2026.
https://www.oncnursingnews.com/view/encorafenib-binimetinib-showcases-sustained-responses-in-braf-v600-mutant-melanoma - FDA approves encorafenib with binimetinib for metastatic non-small cell lung cancer with a BRAF V600E variant. Oncology Nursing Society. October 2023. Accessed November 16, 2026.
https://www.ons.org/publications-research/voice/news-views/10-2023/fda-approves-encorafenib-binimetinib-metastatic - Dobkowski D, Fischer L. FDA approves encorafenib/binimetinib for BRAF V600E+ NSCLC. Oncology Nursing News. October 11, 2023. Accessed November 16, 2026.
https://www.oncnursingnews.com/view/fda-approves-encorafenib-binimetinib-for-braf-v600e-nsclc
Related to this article








